Biodesix Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Biodesix de 34.9% y 18% respectivamente, mientras que el BPA crecerá en un 47.5% al año.

Información clave

34.9%

Tasa de crecimiento de los beneficios

47.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare	17.2%
Tasa de crecimiento de los ingresos	18.0%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	20 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

Jun 12

With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Mar 03

Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

Jan 04

Need To Know: Analysts Just Made A Substantial Cut To Their Biodesix, Inc. (NASDAQ:BDSX) Estimates

Nov 25

Bearing In On Biodesix

Sep 13

Time To Worry? Analysts Are Downgrading Their Biodesix, Inc. (NASDAQ:BDSX) Outlook

Aug 16

Biodesix: Continued Concerns After The Boom-Bust Cycle

Jul 14

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:BDSX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	101	-25	-6	-5	2
12/31/2025	83	-39	-16	-17	4
12/31/2024	67	-45	-40	-41	4
3/31/2024	55	-47	-46	-30	N/A
12/31/2023	49	-52	-46	-23	N/A
9/30/2023	44	-63	-45	-23	N/A
6/30/2023	42	-66	-46	-29	N/A
3/31/2023	41	-69	-50	-40	N/A
12/31/2022	38	-65	-49	-45	N/A
9/30/2022	36	-58	-45	-43	N/A
6/30/2022	31	-56	-43	-41	N/A
3/31/2022	32	-52	-32	-30	N/A
12/31/2021	55	-43	-31	-28	N/A
9/30/2021	74	-34	-29	-27	N/A
6/30/2021	77	-32	-26	-23	N/A
3/31/2021	69	-29	-31	-28	N/A
12/31/2020	46	-31	-24	-21	N/A
9/30/2020	27	-33	-22	-18	N/A
6/30/2020	22	-34	-23	-21	N/A
3/31/2020	23	-33	-23	-21	N/A
12/31/2019	25	-31	-24	-22	N/A
12/31/2018	20	-26	-18	-18	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que BDSX siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que BDSX siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que BDSX siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (18% al año) de BDSX crezcan más rápidamente que los del mercado US (8.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 18% al año) de BDSX crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de BDSX se prevé que sea elevada dentro de 3 años.

Biodesix Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Biodesix, Inc. Provides Revenue Guidance for the Year 2024

Biodesix, Inc. Provides Revenue Guidance for the Year 2023

Consensus EPS estimates upgraded to US$0.68 loss

Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2023

Price target decreased to US$5.00

Biodesix, Inc. Provides Earnings Guidance for the Year 2022

Recent updates

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

New major risk - Shareholder dilution

Biodesix, Inc. to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. to Report Q1, 2024 Results on May 08, 2024

Biodesix, Inc., Annual General Meeting, May 21, 2024

Biodesix, Inc. announced that it expects to receive $34.999422 million in funding

Biodesix, Inc. has completed a Follow-on Equity Offering in the amount of $20.000607 million.

With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2024

Biodesix, Inc. to Report Q4, 2023 Results on Mar 01, 2024

President notifies of intention to sell stock

Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

Biodesix, Inc. Enhances Access to Nodify Lung Testing with Launch of New Blood Draw Method

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2023

Biodesix, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New major risk - Share price stability

Biodesix, Inc. Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer

Independent Director recently bought US$217k worth of stock

Biodesix, Inc. Announces Presentation of New Nodify XL2(R) Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer

Consensus EPS estimates upgraded to US$0.68 loss

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. to Report Q2, 2023 Results on Aug 07, 2023

It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks

Biodesix, Inc. Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating That the Nodify XL2 Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

Biodesix, Inc. Receives Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services

Biodesix Completes Enrollment of Insight Study Assessing Clinical Utility of the Veristrat®? Blood-Based Host Immune Classifier

Biodesix, Inc. Announces Resignation of Ryan Siurek as Chief Accounting Officer, Effective July 3, 2023

Independent Director recently bought US$65k worth of stock

Biodesix, Inc. Announces New Clinical Utility Evidence for the Nodify XL2 Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Independent Director recently bought US$125k worth of stock

Biodesix Announces First Four Private Payer Coverage Policies for the Nodify Xl2® Test

Biodesix Announces First Four Private Payer Coverage Policies for the Nodify Xl2® Test

Biodesix, Inc. Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors and Audit Committee of the Board, Effective January 3, 2023

Independent Director recently bought US$148k worth of stock

Biodesix, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Price target decreased to US$5.00

Biodesix, Inc. Presents New Data from the Insight Study At the 2022 Society for Immunotherapy of Cancer 37Th Annual Meeting

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Provides Earnings Guidance for the Year 2022

Biodesix, Inc. to Report Q3, 2022 Results on Nov 03, 2022

A Second Look At Biodesix

Biodesix, Inc. Provides Revenue Guidance for the Third Quarter 2022

Biodesix expects Q3 revenue above the consensus

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2022

Biodesix GAAP EPS of -$0.40 beats by $0.07, revenue of $10.95M beats by $2.12M

Biodesix, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Biodesix, Inc.(NasdaqGM:BDSX) dropped from Russell 2000 Growth Index

Biodesix, Inc. Obtains Medicare Coverage for the Nodify CDT Lung Nodule Test

Biodesix: Bad Diagnosis

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2022

Price target decreased to US$9.00

High number of new directors

Consensus forecasts updated

Independent Director recently bought US$5.0m worth of stock

Biodesix, Inc., Annual General Meeting, May 24, 2022

Consensus revenue estimates increase by 10%

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Analysts' Revenue Estimates For Biodesix, Inc. (NASDAQ:BDSX) Are Surging Higher

Biodesix, Inc. Announces Impactful Clinical Data on the Primary Immune Response Test at IASLC 2022 Therapies of Lung Cancer Meeting